Vincerx Pharma, Inc. (VINC)

0,6187 +0,0187 (+3,12%) Ab 11:03AM EDT. Markt geöffnet.

Vincerx Pharma, Inc.

260 Sheridan Avenue
Suite 400
Palo Alto, CA 94306
United States
650 800 6676
https://vincerx.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 42

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Ahmed M. Hamdy M.D.	Co-Founder, Chairman & CEO	657,54k	N/A	1965
Dr. Raquel E. Izumi Ph.D.	Co-Founder, President, COO, Secretary & Director	591,54k	N/A	1970
Mr. Alexander A. Seelenberger M.B.A.	Chief Financial Officer	491,69k	N/A	1979
Mr. Tom C. Thomas J.D.	Founder, General Counsel & Chief Legal Officer	444,14k	N/A	1960
Dr. John C. Byrd M.D.	Founder & Chairman of Scientific Advisory Board	N/A	N/A	N/A
Dr. Hans-Georg Lerchen Ph.D.	Chief Scientific Officer	N/A	N/A	N/A
Ms. Gabriela Jairala	Sr Executive Director of Investor Relations & Corporate Communications	N/A	N/A	N/A
Ms. Karen Quarford	Vice President of Quality Operations & Compliance	N/A	N/A	N/A
Ms. Melissa Merrick SPHR	Senior Director of People & Culture and Head of Human Resource	N/A	N/A	N/A
Dr. Beatrix Stelte-Ludwig Ph.D.	Executive Chief Development Officer	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors. Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies. Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.

Corporate Governance

Vincerx Pharma, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.